Genta Moves to New Corporate Headquarters
LEXINGTON, Mass., June 7 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA), a developer of antisense-based cancer therapy, announced today that it has moved its worldwide corporate headquarters to accommodate the Company's focus on the antisense-based cancer therapy development, and to better manage its resource efficiency.
Effective immediately, Genta's new headquarters is
99 Hayden Avenue, Suite 200
Lexington, MA 02421
Tel: 781-860-5150, Fax: 781-860-5137
E-mail address: info@genta.com
"The move to our new headquarters is further evidence of our commitment to reduce expenses while focusing on the development of our G3139 Anticode(TM) oligonucleotide technology," said Kenneth G. Kasses, Ph.D., President and CEO of Genta. "In April, we closed our operations in San Diego, CA and moved to Lexington, Mass., which will allow us to more effectively and efficiently manage our clinical trials."
Genta Incorporated is a biopharmaceutical company whose strategy consists of building a product and technology portfolio concentrating on its Anticode(TM) (antisense) products intended to treat cancer at its genetic source.
To receive Genta Incorporated's latest news release and other corporate announcements via fax, at no cost, dial 1-800-PRO-INFO; use the Company's symbol GNTA. Or visit The Financial Relations Board's web site at www.frbinc.com.
SOURCE Genta Incorporated
CO: Genta Incorporated
ST: Massachusetts
IN: MTC
SU:
06/07/99 10:16 EDT prnewswire.com |
